博瑞医药(688166.SH)发布半年度业绩，归母净利润1717万元，同比下降83.85%

Core Viewpoint - 博瑞医药 reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its business operations and market conditions [1] Financial Performance - The company achieved a revenue of 537 million yuan, representing a year-on-year decrease of 18.28% [1] - The net profit attributable to shareholders was 17.17 million yuan, down 83.85% compared to the previous year [1] - The non-recurring net profit was 14.37 million yuan, reflecting a decline of 86.35% year-on-year [1] - Basic earnings per share stood at 0.04 yuan [1]